- Boustead Securities
Boustead Client Know Labs Confirms Particle Bulb Kills SARS-CoV-2
Boustead Securities, LLC (“Boustead”) client Know Labs, Inc. (OTCQB: KNWN), an emerging leader in non-invasive medical diagnostics, through its proprietary electromagnetic energy technology platforms, has shared with the public preliminary study results from Texas Biomedical Research Institute (Texas Biomed) indicating the Particle bulb’s ability to inactivate SARS-CoV-2, the virus that causes COVID-19. In addition, the Particle bulb can kill a number of common household bacteria and germs, for example E. Coli, Salmonella, and Staphylococcus.
Rather than using dangerous UV-C light to kill germs quickly, Particle’s method is “low and slow.” Particle bulb disinfects germs using Gentle UV, a blend of UV-A light, for longer periods, allowing it to be used safely near people in homes, businesses, and institutions.
Multiple tests performed by Texas Biomed demonstrated a 95% reduction in the SARS-CoV-2 virus after 5 hours of exposure to the Particle bulb; a 99% reduction in 6 hours; and a 99.9% reduction in 8 hours.
“We were very pleased to work with Texas Biomed because of their reputation as a global leader in eradicating infectious diseases and we’re really excited by these results,” said Know Labs CEO, Phil Bosua. Texas Biomed is a world-renowned, independent, non-profit biomedical research institute specializing in infectious diseases. Home to a CDC-regulated biosafety level-4 laboratory, Texas Biomed develops vaccines and therapies to successfully treat some of the world’s deadliest diseases, including COVID-19. Viraj Kulkarni, Ph.D., Staff Scientist at the Disease Intervention & Prevention Division at Texas Biomed, stated, "Study results indicated Particle bulb is effective at inactivating the virus that causes COVID-19. Technologies, like Particle, have great potential in assisting the world.” Boustead served as exclusive placement agent and advisor for the Company’s recently completed $14.2m financing and serves as exclusive advisor for Know Labs planned uplisting. Sign up for updates at particlebulb.com
About Know Labs, Inc. Know Labs, Inc. is a public company whose shares trade under the stock symbol “KNWN.” The Company’s technology uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. The Company refers to its technology as Bio-RFID™. The Bio-RFID technology can be integrated into a variety of wearable, mobile or bench-top form factors. This patented and patent pending technology makes it possible to effectively conduct analyses that could only previously be performed by invasive and/or expensive and time-consuming lab-based tests. The Company’s first product will be the non-invasive UBAND™ Continuous Glucose Monitor (CGM). Those wishing to stay up to date on the developments at Know Labs can subscribe to the Company’s YouTube channel at this link. For more information, visit the company’s website at www.knowlabs.co
About Texas Biomedical Research Institute Texas Biomed is an independent, nonprofit research institute that has delivered high quality and reliable scientific data, spanning basic discovery through preclinical development. Texas Biomed performs both independent, grant- funded research and contract research, contributing to the development of diagnostics, therapies and vaccines to combat the world’s deadliest diseases. Texas Biomed is one of the world’s leading independent biomedical research institutions dedicated to eradicating infection and advancing health worldwide through innovative biomedical research. Texas Biomed partners with researchers and institutions around the world to develop therapeutics and vaccines against viral pathogens causing AIDS, hepatitis, hemorrhagic fever, tuberculosis and parasitic diseases responsible for malaria and schistosomiasis disease. The Institute has programs in host-pathogen interaction, disease intervention and prevention and population health to understand the links between infectious diseases and other diseases such as aging, cardiovascular disease, diabetes and obesity. For more information on Texas Biomed, go to www.TxBiomed.org
About Boustead Securities, LLC
Boustead Securities, LLC (“Boustead”) is an investment banking firm that executes and advises on IPOs, mergers and acquisitions, capital raises and restructuring assignments in a wide array of industries, geographies and transactions, for a broad client base. Boustead’s core value proposition is the ability to create opportunity through innovative solutions and tenacious execution. With experienced professionals in the United States, Boustead’s team moves quickly and provides a broad spectrum of sophisticated financial advice and services. Boustead is a majority owned subsidiary of Boustead & Company Limited, a diversified non-bank financial institution. For more information, please visit www.boustead1828.com
Form CRS/Reg BI Disclaimer:
Boustead Securities, LLC, Sutter Securities Inc., and Sutter Securities Clearing,LLC (SSC) are registered with the Securities and Exchange Commission (SEC) as broker-dealers and are members of the Financial Industry Regulatory Authority (FINRA) and the Securities Investor Protection Corporation (SIPC). Brokerage and investment advisory services and fees differ and it is important for you to understand these differences. Free and simple tools are available to research firms and financial professionals at Investor.gov/CRS, which also provides educational materials about broker-dealers, investment advisers, and investing. When we provide you with a recommendation, we have to act in your best interest and not put our interest ahead of yours. At the same time, the way we make money creates a conflict with your interests. Please strive to understand and ask us about these conflicts because they can affect the recommendations we provide you. There are many risks involved with investing. For Boustead Securities customers and clients, please see our Regulation Best Interest Relationship Guide on the Form CRS Reg BI page on our website at https://www.boustead1828.com/form-crs-reg-bi. For Sutter Securities’ and Sutter Securities Clearing’s customers and clients, please see the Form CRS on the website at https://suttersecurities.com/wp-content/uploads/2020/12/Sutter-Form-CRS-combined-121020.pdf. For FlashFunders’ visitors, you may review the Form CRS of Boustead Securities, Sutter Securities and Sutter Securities Clearing under the Form CRS section. Please also carefully review and verify the accuracy of the information you provide us on account applications, subscription documents and others.
Cautionary Statement Concerning Forward-Looking Statements
This document contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this document and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this document and other statements made from time to time by us or our representatives might not occur.